- Home
- JRS vs BWAY Comparison
JRS vs BWAY Comparison
Compare JRS & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JRS
- BWAY
- Stock Information
- Founded
- JRS 2001
- BWAY 2003
- Country
- JRS United States
- BWAY Israel
- Employees
- JRS N/A
- BWAY N/A
- Industry
- JRS Finance/Investors Services
- BWAY Medical/Dental Instruments
- Sector
- JRS Finance
- BWAY Health Care
- Exchange
- JRS Nasdaq
- BWAY Nasdaq
- Market Cap
- JRS 241.3M
- BWAY 280.7M
- IPO Year
- JRS N/A
- BWAY 2019
- Fundamental
- Price
- JRS $8.11
- BWAY $16.89
- Analyst Decision
- JRS
- BWAY Strong Buy
- Analyst Count
- JRS 0
- BWAY 2
- Target Price
- JRS N/A
- BWAY $18.00
- AVG Volume (30 Days)
- JRS 86.6K
- BWAY 76.3K
- Earning Date
- JRS 01-01-0001
- BWAY 11-11-2025
- Dividend Yield
- JRS 8.87%
- BWAY N/A
- EPS Growth
- JRS N/A
- BWAY 515.14
- EPS
- JRS N/A
- BWAY 0.11
- Revenue
- JRS N/A
- BWAY $46,084,000.00
- Revenue This Year
- JRS N/A
- BWAY $339.49
- Revenue Next Year
- JRS N/A
- BWAY $21.74
- P/E Ratio
- JRS N/A
- BWAY $53.75
- Revenue Growth
- JRS N/A
- BWAY 26.50
- 52 Week Low
- JRS $5.95
- BWAY $7.84
- 52 Week High
- JRS $8.00
- BWAY $16.98
- Technical
- Relative Strength Index (RSI)
- JRS 52.02
- BWAY 70.40
- Support Level
- JRS N/A
- BWAY $15.01
- Resistance Level
- JRS $8.38
- BWAY $16.09
- Average True Range (ATR)
- JRS 0.08
- BWAY 0.68
- MACD
- JRS -0.29
- BWAY -0.06
- Stochastic Oscillator
- JRS 96.78
- BWAY 95.82
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.